



Design And Development Of Taste Masked Oral Disintegrating Tablets For Anti-Vertigo Drug

Mr PratitAgrawal^{1*}, Dr Amit Chouhan²

¹ResearchScholar, ²Professor
Institute of Pharmaceutical Science &
Research Sardar Patel University Balaghat
(M.P.), India

Abstract: Mouth dissolving tablets are those that dissolve or disintegrate quickly in the oral cavity, resulting in solution or suspension. In the present study Mouth dissolving tablet of Meclizine was prepared by direct compression method using crosspovidone, Crosscarmellose and Indion 414, as superdisintegrants. FT-IR study shows that there is no significant interactions occur between drug and excipient. The tablets prepared were evaluated for various parameters like various density parameters, thickness, hardness, friability, disintegration time, wetting time and In-vitro dissolution time. All the parameters were found to be within limits. The developed formulation of Meclizine batch F8 (9 % Indion 414) showed good palatability and dispersed within 30 seconds as compared to crosscarmellose.

Index Terms-Mouth dissolving tablets, crosspovidone, superdisintegrants, Indion414 andFT-IR

I. INTRODUCTION

Drug Delivery Systems (DDS) area strategic tool for expanding markets/indications, extending product life cycles and generating opportunities. DDS make a significant contribution to global pharmaceutical sales through market segmentation, and are moving rapidly. Drug delivery systems are becoming increasingly sophisticated as pharmaceutical scientists acquire a better understanding of the physicochemical and biochemical parameters pertinent to their performance¹.

Despite of tremendous advancements in drug delivery, the oral route remains the perfect route for the administration of therapeutic agents because of low cost of therapy, ease of administration, accurate dosage, self - medication, pain avoidance, versatility, leading to high levels of patient compliance. Tablets and capsules are the most popular dosage forms. But one important drawback of such dosage forms is 'Dysphagia' or difficulty in swallowing. This is seen to afflict nearly 35% of the general population. This disorder is also associated with a number of conditions like:

1. Parkinsonism
2. Motion sickness
3. Unconsciousness
4. Elderly patients
5. Children
6. Mentally disabled persons
7. Unavailability of water

Improved patient compliance has achieved enormous demand. Consequently demand for their technologies is also increasing many folds. To develop a chemical entity, a lot of money, hard work and time are required. So focus is rather being laid on the development of new drug delivery systems for already existing drugs, with enhanced efficacy and bioavailability, thus reducing the dose and dosing frequency to minimize the side effects. It is always the aim of a scientist or a dosage form designer to

enhance the safety of a drug molecule while maintaining its therapeutic efficacy. Recent advances in Novel Drug Delivery Systems (NDDS) aim for the same by formulating a dosage form, convenient to be administered so as to achieve better patient compliance. Pharmaceutical technologists have put in their best efforts to develop a Fast Dissolving Drug Delivery System, i.e DispersibleTablet1.

Orally Disintegrated Tablet (OODT)

It is a tablet that disintegrates and dissolves rapidly in the saliva, within a few seconds without the need of drinking water or chewing. A Dispersible tablet usually dissolves in the oral cavity within 15 s to 3 min. Most of the ODTs include certain super disintegrants and taste masking agents.

Ideal properties of ODT

1. A Orally Disintegrated Tablet should
 - a. Not require water or other liquid to swallow.
 - b. Easily dissolve or disintegrate in saliva within a few seconds.
 - c. Have a pleasing taste.
 - d. Leave negligible or no residue in the mouth when administered.
2. Be portable and easy to transport.
3. Be able to be manufactured in a simple conventional manner within low cost.
4. Be less sensitive to environmental conditions like temperature, humidity etc1.

Advantages of ODT

1. No need of water to swallow the tablet.
2. Can be easily administered to pediatric, elderly and mentally disabled patients.
3. Accurate dosing as compared to liquids.
4. Dissolution and absorption of drug is fast, offering rapid onset of action.
5. Bioavailability of drug is increased as some drugs are absorbed from mouth, pharynx and esophagus through saliva passing down into the stomach.
6. Advantageous over liquid medication in terms of administration as well as transportation.
7. First pass metabolism is reduced, thus offering improved bioavailability and thus reduced dose and side effects.
8. Free of risk of suffocation due to physical obstruction when swallowed, thus offering improved safety.
9. Suitable for sustained/controlled release actives1.




Fig.1: Advantages of ODT

1.6 Mechanism of action of disintegrants

The tablet breaks to primary particles by one or more of the mechanisms listed below:-

- By capillary action
- By swelling
- Because of heat of wetting
- Due to release of gases
- By enzymatic action
- Due to disintegrating particle/particle repulsive forces
- Due to deformation




Fig.2: Mechanism of Action of Superdisintegrants

2. Formulation Development

The mouth dissolving tablet prepared by superdisintegrant addition method. The tablets were formulated employing direct compression method using 8 mm biconcave punches. It is the process by which tablets are compressed directly from mixtures of the drug and excipients without preliminary treatment such as granulation.

Drug (10 mg), super disintegrants in different ratios and excipients were blended using mortar and pestle. The drug and the disintegrants were sieved through mesh # 120 before blending. The mixture was evaluated for angle of repose, bulk density and compressibility. The mixture was mixed with 1% magnesium stearate as lubricant and mint as flavoring agent. The powder blends were then compressed by using Fluidpack multistation rotary tablet machine using 8 mm punch. The hardness was adjusted to 2-5 kg/cm².

Table 1. Formulation of Mouth-dissolving tablets

Ingredients(mg)	F1	F2	F3	F4	F5	F6	F7	F8	F9
Meclizine	25	25	25	25	25	25	25	25	25
MCC(PH-102)	14	14	14	14	14	14	14	14	14
Crosscarmellosesodium	9	13.5	18	-	-	-	-	-	-
Crosspovidone	-	-	-	9	13.5	18	-	-	-
Indion414	-	-	-	-	-	-	9	13.5	18
Povidone	1	1	1	1	1	1	1	1	1
PearlitolSD200	89	84.5	80	89	84.5	80	89	84.5	80
Aspartame	q.s	q.s	q.s	q.s	q.s	q.s	q.s	q.s	q.s
Talcumpowder	1%	1%	1%	1%	1%	1%	1%	1%	1%
Mg.Stearate	1%	1%	1%	1%	1%	1%	1%	1%	1%

3. Evaluation Studies of powder parameters (Pre-Formulation):-

Table No.2: Preformulation studies of Various batches

Batch	Angle of Repose(θ)/ $\pm$ SD	Bulk Density (g/cc)/ $\pm$ SD	Tapped Density (g/cc)/ $\pm$ SD	(%) Compressibility/ $\pm$ SD	Hausner's Ratio/ $\pm$ SD
F1	33.13 ⁰ $\pm$ 0.003	0.47 $\pm$ 0.007	0.54 $\pm$ 0.003	14.23 $\pm$ 1.601	1.16 $\pm$ 0.802
F2	32.55 ⁰ $\pm$ 0.201	0.44 $\pm$ 0.017	0.50 $\pm$ 0.017	12.62 $\pm$ 1.032	1.14 $\pm$ 0.010
F3	33.25 ⁰ $\pm$ 0.045	0.56 $\pm$ 0.024	0.66 $\pm$ 0.038	15.15 $\pm$ 1.926	1.16 $\pm$ 0.802
F4	31.21 ⁰ $\pm$ 0.675	0.48 $\pm$ 0.003	0.54 $\pm$ 0.003	12.40 $\pm$ 0.954	1.14 $\pm$ 0.010
F5	38.36 ⁰ $\pm$ 1.852	0.45 $\pm$ 0.014	0.48 $\pm$ 0.024	5.20 $\pm$ 1.590	1.06 $\pm$ 0.017
F6	33.74 ⁰ $\pm$ 0.219	0.47 $\pm$ 0.007	0.50 $\pm$ 0.017	5.25 $\pm$ 1.573	1.06 $\pm$ 0.017
F7	32.05 ⁰ $\pm$ 0.378	0.48 $\pm$ 0.003	0.56 $\pm$ 0.003	6.36 $\pm$ 1.180	1.14 $\pm$ 0.010
F8	31.03 ⁰ $\pm$ 0.738	0.51 $\pm$ 0.007	0.54 $\pm$ 0.003	4.42 $\pm$ 1.866	1.04 $\pm$ 0.024
F9	32.82 ⁰ $\pm$ 0.106	0.53 $\pm$ 0.014	0.60 $\pm$ 0.017	11.66 $\pm$ 0.692	1.13 $\pm$ 0.007


4. Evaluation of Tablet (Post-Formulation):-

Table No.3: Physical evaluation of formulated tablet batches


Parameter	F1	F2	F3	F4	F5	F6	F7	F8	F9
Thickness(mm) / $\pm$ SD	2.61 $\pm$ 0.00	2.64 $\pm$ 0.01	2.63 $\pm$ 0.01	2.62 $\pm$ 0.01	2.64 $\pm$ 0.01	2.61 $\pm$ 0.00	2.51 $\pm$ 0.02	2.52 $\pm$ 0.02	2.54 $\pm$ 0.01
Hardness (kg/cm ²)/ $\pm$ SD	3.6 $\pm$ 0.17	3.2 $\pm$ 0.19	2.9 $\pm$ 0.07	3.4 $\pm$ 0.10	3.1 $\pm$ 0.00	3.4 $\pm$ 0.10	3.2 $\pm$ 0.19	2.9 $\pm$ 0.07	2.5 $\pm$ 0.21
Friability (%w/w)/ $\pm$ SD	0.21 $\pm$ 0.11	0.73 $\pm$ 0.06	1.16 $\pm$ 0.21	0.53 $\pm$ 0.00	0.41 $\pm$ 0.04	1.07 $\pm$ 0.18	0.12 $\pm$ 0.14	0.32 $\pm$ 0.07	0.33 $\pm$ 0.07
Wetting time(sec)/ $\pm$ SD	19 $\pm$ 0.51	14 $\pm$ 1.21	16 $\pm$ 0.50	15 $\pm$ 0.86	18 $\pm$ 0.19	19 $\pm$ 0.55	16 $\pm$ 0.50	12 $\pm$ 1.92	28 $\pm$ 3.73
Disintegration time (sec)/ $\pm$ SD	25 $\pm$ 0.86	21 $\pm$ 0.54	22 $\pm$ 0.19	27 $\pm$ 1.57	24 $\pm$ 0.51	25 $\pm$ 0.86	23 $\pm$ 0.15	17 $\pm$ 1.96	19 $\pm$ 1.25
Drug content (%w/v)/ $\pm$ SD	87.53 $\pm$ 0.20	87.80 $\pm$ 0.10	88.16 $\pm$ 0.01	87.48 $\pm$ 0.22	87.80 $\pm$ 0.10	78.40 $\pm$ 3.43	87.96 $\pm$ 0.05	95.11 $\pm$ 0.93	92.76 $\pm$ 1.64
Dissolution (%w/v)/ $\pm$ SD	67.71 $\pm$ 5.83	81.32 $\pm$ 1.02	69.0 $\pm$ 5.38	89.43 $\pm$ 1.84	85.53 $\pm$ 0.46	87.93 $\pm$ 1.31	89.98 $\pm$ 2.03	95.48 $\pm$ 3.98	91.68 $\pm$ 2.63

TableNo.3:StandardCalibrationcurve

Conc.(mcg/ml)	Absorbance	±S.D.
0	0.0000	0.00
15	0.225	±0.036
30	0.285	±0.012
45	0.341	±0.01
60	0.401	±0.034
75	0.438	±0.049
90	0.523	±0.084


**Fig.No.3:StandardcalibrationcurveofMECLIZINE****TableNo.4:Comparativestudyof%DrugreleasefromMouthdissolvingtabletsofBatchF1,F2and F3**

Time n Min	%drugrelease		
	F1	F2	F3
30 sec	9.44	14.73	11.08
60 sec	20.41	29.76	21.87
90 sec	31.71	48.40	33.40
2	43.18	61.49	44.98
3	53.33	77.80	56.80
4	67.71	81.32	69.0


**Fig.No.4:Comparativestudyof%Drugrelease(BatchF1,F2and F3)**

TableNo.5:Comparativestudyof%DrugreleasefromMouthdissolvingtabletsofBatchF4,F5and F6

Time n Min	%drugrelease		
	F4	F5	F6
30 sec	13.72	14.96	13.5
60 sec	27.75	29.95	27.47
90 sec	41.55	45.7	41.73
2	57.26	61.71	36.96
3	73.12	78.1	72.6
4	89.43	85.3	87.93

**FigNo.6:Comparativestudyof%Drugrelease(BatchF4,F5and F6)****TableNo.6:Comparativestudyof%DrugreleasefromMouthdissolvingtabletsofBatchF7,F8and F9**

Time n Min	%drugrelease		
	F7	F8	F9
30 sec	14.58	14.73	14.17
60 sec	29.55	29.33	28.68
90 sec	45.0	45.08	43.13
2	61.61	61.28	59.17
3	77.36	78.16	75.15
4	89.98	95.48	91.68


**FigNo.7:Comparativestudyof%Drugrelease(BatchF7,F8and F9)**

5. Mechanism of Release from Matrix tablets:


From the data obtained after applying all suitable mathematical models we can conclude that the optimized formulations selected are proposed to explain the mechanism of release of drug from formulation

Tableno.7: Drug release kinetic study of optimized batch


MODELS		F ₈ (MECLIZINE)
Korsmeyer-peppas	n	0.987
Zero order	R	0.976
First order	R	0.846
Higuchi model	R	0.996
Best fit model		Higuchi




FigNo.8: Curve fitting data of the release rate profile of zero order.



FigNo.9: Curve fitting data of the release rate profile of first order.



FigNo.10: Curve fitting data of the release rate profile of Higuchi model



FigNo.11:CurvefittingdataofthereleaserateprofileofKorsmeyer-peppas

4. Conclusion

In present study Meclizine Mouth dissolving tablet prepared using different types and concentrations of superdisintegrant by direct compression method which was confirmed by various characterization and evaluation studies. Indion 414 as superdisintegrant gives better result as compared to crosscarmellose sodium and crosspovidone. Tablets disintegrate within 30 sec in mouth having better mouth feel.

References

1. Tejvir Kaur, Bhawandeep Gill, Sandeep Kumar, G.D. Gupta, "Mouth Dissolving Tablets: A Novel Approach To Drug Delivery", International Journal of Current Pharmaceutical Research, Vol 3, Issue 1, 2011, 1-7.
2. Abdul Sayeed, Mohd. Hamed Mohiuddin, "Mouth dissolving tablets: An Overview", International Journal of Research in Pharmaceutical and Biomedical Sciences, Vol. 2 (3) Jul – Sep 2011, 959-970.
3. Kamal Saroha, Pooja Mathur*, Surender Verma, Navneet Syan and Ajay Kumar, "Mouth dissolving tablets: An overview on future compaction in oral formulation technologies", Pelagia Research Library, Der Pharmacia Sinica, 2010, 1 (1):179-187.
4. Ajoybera and ashish mukherjee, "A detailed study of mouth dissolving drug delivery system", acta chim. Pharm. Indica: 3(1), 2013, 65-93.
5. Dalishukla, subhashish chakraborty, sanjaysingh, brahmeshwar mishra, "mouth dissolving tablets ii: an overview of evaluation techniques", scientia pharmaceutica. 2009; 77; 327-341.
6. Velmurugan Sand Sundar Vinushitha, "Oral Disintegrating Tablets: An Overview", International Journal of Chemical and Pharmaceutical Sciences, 2010, Dec., Vol.1 (2), 1-12.
7. Himanshu Deshmukh, Chandrashekhara S.*, Nagesh C., Amol Murade, Shridhar Usgaunkar, "Superdisintegrants: A Recent Investigation and Current Approach", Asian J. Pharm. Tech. 2012; Vol. 2: Issue 1, Pg 19-25.
8. N. Damodharan*, M. Mothilal, G. Vasundhara, "Formulation and Optimization of Fast Dissolving", International Journal of PharmTech Research Cinnarizine Tablets, April-June 2010, Vol.2, No.2, pp 1095-1100.
9. SHIR SANDS B, SARASI JASURESH, P. V. SWAMY, "Formulation Design of Novel Fast Disintegrating Tablet of Prochlorperazine Maleate", International Journal of PharmTech Research, Jan-Mar 2010, Vol.2, No.1, pp 125-129.

10. Patel NJ, Dr. C.S.R. Lakshmi, Hitesh P. Patel, Sagar Akul, "FORMULATION AND EVALUATION OF ORAL DISPERSIBLE TABLETS OF CINNARIZINE USING SUBLIMATION TECHNIQUE", International Journal of Pharmaceutical Sciences Review and Research, Volume 6, Issue 2, January – February 2011; PP 178-182.

